Anti-CD45RA/ PTPRC isoform RA monoclonal antibody
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T43115-8-Ab-1/ GM-Tg-hg-T43115-8-Ab-2 | Anti-Human CD45RA monoclonal antibody | Human |
GM-Tg-hg-T43115-8-Ab-3/ GM-Tg-hg-T43115-8-Ab-4 | Anti-Human CD45RA monoclonal antibody | Human |
GM-Tg-rg-T43115-8-Ab-1/ GM-Tg-rg-T43115-8-Ab-2 | Anti-Rat CD45RA monoclonal antibody | Rat |
GM-Tg-mg-T43115-8-Ab-1/ GM-Tg-mg-T43115-8-Ab-2 | Anti-Mouse CD45RA monoclonal antibody | Mouse |
GM-Tg-cynog-T43115-8-Ab-1/ GM-Tg-cynog-T43115-8-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD45RA monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T43115-8-Ab-1/ GM-Tg-felg-T43115-8-Ab-2 | Anti-Feline CD45RA monoclonal antibody | Feline |
GM-Tg-cang-T43115-8-Ab-1/ GM-Tg-cang-T43115-8-Ab-2 | Anti-Canine CD45RA monoclonal antibody | Canine |
GM-Tg-bovg-T43115-8-Ab-1/ GM-Tg-bovg-T43115-8-Ab-2 | Anti-Bovine CD45RA monoclonal antibody | Bovine |
GM-Tg-equg-T43115-8-Ab-1/ GM-Tg-equg-T43115-8-Ab-2 | Anti-Equine CD45RA monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T43115-8-Ab-1/ GM-Tg-hg-T43115-8-Ab-2; GM-Tg-hg-T43115-8-Ab-3/ GM-Tg-hg-T43115-8-Ab-4; GM-Tg-rg-T43115-8-Ab-1/ GM-Tg-rg-T43115-8-Ab-2; GM-Tg-mg-T43115-8-Ab-1/ GM-Tg-mg-T43115-8-Ab-2; GM-Tg-cynog-T43115-8-Ab-1/ GM-Tg-cynog-T43115-8-Ab-2; GM-Tg-felg-T43115-8-Ab-1/ GM-Tg-felg-T43115-8-Ab-2; GM-Tg-cang-T43115-8-Ab-1/ GM-Tg-cang-T43115-8-Ab-2; GM-Tg-bovg-T43115-8-Ab-1/ GM-Tg-bovg-T43115-8-Ab-2; GM-Tg-equg-T43115-8-Ab-1/ GM-Tg-equg-T43115-8-Ab-2 |
Products Name | Anti-CD45RA monoclonal antibody |
Format | mab |
Target Name | CD45RA |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse/Human |
CH1+2+3 Isotype (Receptor identification) |
IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CD45RA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-ab-029 | Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-CD45RA Antibody: Anti-B220/CD45/GP180/L-CA/LCA/LY5/T200 therapeutic antibody |
Biosimilar | GMP-Bios-INN-875 | Pre-Made Iodine (131I) Apamistamab Biosimilar, Radiolabelled Antibody, Anti-CD45RA Antibody: Anti-B220/CD45/GP180/L-CA/LCA/LY5/T200 therapeutic antibody |
Target information
Target ID | GM-T43115-8 |
Target Name | CD45RA |
Gene ID | 1957 |
Gene Symbol and Synonyms | CD45RA, LCA-RB, T200, PTPRC isoform RA, Leukocyte common antigen RA |
Uniprot Accession | P08575 |
Uniprot Entry Name | CD45R_HUMAN |
Protein Sub-location | Transmembrane Protein (Leukocyte surface antigen) |
Category | Therapeutic Target, Immune Checkpoint |
Disease | Acute Myeloid Leukemia (AML), Autoimmune Diseases, Transplant Rejection |
Gene Ensembl | ENSG00000170361 |
Target Classification | Leukocyte differentiation marker, Immune Receptor Modulator |
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM's Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.